{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:55:50Z","timestamp":1791312950093,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dmd.2025.100096","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T23:12:37Z","timestamp":1747091557000},"page":"100096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations"],"prefix":"10.1016","volume":"53","author":[{"given":"Sumit","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-1839","authenticated-orcid":false,"given":"Mary F.","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4820-8455","authenticated-orcid":false,"given":"Jashvant D.","family":"Unadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100096_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6904-2-2","article-title":"Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers","volume":"2","author":"Ammon","year":"2002","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100096_bib2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0026-895X(24)12042-1","article-title":"In vitro interaction of codeine and diclofenac","volume":"28","author":"Ammon","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cts.13425","article-title":"The safety and efficacy of low oral doses of cannabidiol: an evaluation of the evidence","volume":"16","author":"Arnold","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.dmd.2025.100096_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jinorgbio.2018.03.016","article-title":"Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2","volume":"184","author":"Arnold","year":"2018","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.dmd.2025.100096_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/dmd.118.084301","article-title":"Optimization of experimental conditions of automated glucuronidation assays in human liver microsomes using a cocktail approach and ultra-high performance liquid chromatography\u2013tandem mass spectrometry","volume":"47","author":"Bad\u00e9e","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.122.001128","article-title":"A physiologically-based pharmacokinetic model for cannabidiol in healthy adults, hepatically-impaired adults, and children","volume":"51","author":"Bansal","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/dmd.121.000734","article-title":"Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes","volume":"50","author":"Bansal","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of cytochrome P450-mediated cannabinoid-drug interactions in healthy adult participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin Pharma and Therapeutics"},{"key":"10.1016\/j.dmd.2025.100096_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/pharmaceutics16020243","article-title":"Cannabinoid-induced stereoselective inhibition of R-S-oxazepam glucuronidation: cannabinoid\u2013oxazepam drug interactions","volume":"16","author":"Bardhi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.dmd.2025.100096_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/dmd.121.000774","article-title":"Comparison of tissue abundance of non-cytochrome P450 drug-metabolizing enzymes by quantitative proteomics between humans and laboratory animal species","volume":"50","author":"Basit","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/psp4.12581","article-title":"Physiologically-based pharmacokinetic modeling of the drug\u2013drug interaction of the ugt substrate ertugliflozin following co-administration with the UGT inhibitor mefenamic acid","volume":"10","author":"Callegari","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100096_bib13","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2025.100096_bib14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/dmd.116.073890","article-title":"Application of static modeling --in the prediction of in vivo drug-drug interactions between Rivaroxaban and antiarrhythmic agents based on in vitro inhibition studies","volume":"45","author":"Cheong","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/pharmaceutics16030418","article-title":"Cannabinoid-induced inhibition of morphine glucuronidation and the potential for in vivo drug\u2013drug interactions","volume":"16","author":"Coates","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.dmd.2025.100096_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pharmthera.2019.05.001","article-title":"A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics","volume":"201","author":"Cox","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100096_bib18","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib41","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jcph.506","article-title":"In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans","volume":"55","author":"Francke","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100096_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/dom.12024","article-title":"Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin","volume":"15","author":"Kasichayanula","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dmd.2025.100096_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100096_bib21","first-page":"82","article-title":"Digoxin and tranilast identified as novel isoform-selective inhibitors of human UDP-glucuronosyltransferase 1A9 (UGT1A9) activity","volume":"44","author":"Lapham","year":"2012","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmd.2025.100096_bib22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.124.001812","article-title":"Clotrimazole identified as a selective UGT2B4 inhibitor using canagliflozin-2'-O-glucuronide formation as a selective UGT2B4 probe reaction","volume":"52","author":"Lapham","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib23","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1124\/dmd.119.087965","article-title":"Ginsenoside Rc is a new selective UGT1A9 inhibitor in human liver microsomes and recombinant human UGT isoforms","volume":"47","author":"Lee","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2174\/1389200023336992","article-title":"Complexities of glucuronidation affecting in vitro in vivo extrapolation","volume":"3","author":"Lin","year":"2002","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmd.2025.100096_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.109.029660","article-title":"Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1124\/dmd.110.037036","article-title":"Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation","volume":"39","author":"Miners","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2025.100096_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108459","article-title":"Drug-drug interactions that alter the exposure of glucuronidated drugs: scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance","volume":"248","author":"Miners","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100096_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107689","article-title":"Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping","volume":"218","author":"Miners","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100096_bib30","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1124\/dmd.121.000530","article-title":"Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14740\/jocmr4159","article-title":"The impact of cannabidiol on psychiatric and medical conditions","volume":"12","author":"Oberbarnscheidt","year":"2020","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.dmd.2025.100096_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/dmd.118.085548","article-title":"Hepatic enzymes relevant to the disposition of (-)-\u03949-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC","volume":"47","author":"Patilea-Vrana","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib34","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1124\/dmd.114.058818","article-title":"In vitro assay of six UDP-glucuronosyltransferase isoforms in human liver microsomes, using cocktails of probe substrates and liquid chromatography\u2013tandem mass spectrometry","volume":"42","author":"Seo","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100096_bib40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100096_bib38","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","article-title":"Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety","volume":"88","author":"Yamaori","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.dmd.2025.100096_bib39","article-title":"Drug-drug interaction potentials of tyrosine kinase inhibitors via inhibition of UDP-glucuronosyltransferases","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T10:08:52Z","timestamp":1750846132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0090955625091056"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100096","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100096"}}